CA2208916A1 - Promotion de la cicatrisation a l'aide de steroides ayant des effets secondaires systemiques reduits comparativement a ceux habituellement associes aux glucocorticoides, aux mineralcorticoides et aux steroides sexuels - Google Patents

Promotion de la cicatrisation a l'aide de steroides ayant des effets secondaires systemiques reduits comparativement a ceux habituellement associes aux glucocorticoides, aux mineralcorticoides et aux steroides sexuels

Info

Publication number: CA2208916A1
Authority: CA; Canada
Prior art keywords: steroids; composition; dione; tetrahydrocortisol; tetrahydrocortisone
Prior art date: 1997-07-03
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002208916A

Other languages

English (en)

Inventor

Michael P. Seed

Chandan Alam

Derek A. Willoughby

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Jagotec AG

Original Assignee

Hyal Pharmaceutical Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-07-03

Filing date

1997-07-03

Publication date

1999-01-03

1997-07-03 Application filed by Hyal Pharmaceutical Corp filed Critical Hyal Pharmaceutical Corp

1997-07-03 Priority to CA002208916A priority Critical patent/CA2208916A1/fr

1998-07-03 Priority to AU82021/98A priority patent/AU8202198A/en

1998-07-03 Priority to PCT/CA1998/000649 priority patent/WO1999001142A1/fr

1999-01-03 Publication of CA2208916A1 publication Critical patent/CA2208916A1/fr

Status Abandoned legal-status Critical Current

Links

150000003431 steroids Chemical class 0.000 title claims abstract description 183
230000000694 effects Effects 0.000 title claims abstract description 45
230000029663 wound healing Effects 0.000 title claims abstract description 30
230000002829 reductive effect Effects 0.000 title claims abstract description 17
239000003862 glucocorticoid Substances 0.000 title claims description 35
239000002395 mineralocorticoid Substances 0.000 title claims description 29
229940037129 plain mineralocorticoids for systemic use Drugs 0.000 title claims description 25
229940037128 systemic glucocorticoids Drugs 0.000 title claims description 24
229920002674 hyaluronan Polymers 0.000 claims abstract description 147
239000000203 mixture Substances 0.000 claims abstract description 104
230000000964 angiostatic effect Effects 0.000 claims abstract description 102
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 92
229960003160 hyaluronic acid Drugs 0.000 claims abstract description 91
230000033115 angiogenesis Effects 0.000 claims abstract description 86
KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 claims abstract description 56
229940099552 hyaluronan Drugs 0.000 claims abstract description 56
206010052428 Wound Diseases 0.000 claims abstract description 40
208000027418 Wounds and injury Diseases 0.000 claims abstract description 40
150000003839 salts Chemical class 0.000 claims abstract description 25
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 22
206010029113 Neovascularisation Diseases 0.000 claims abstract description 18
241000124008 Mammalia Species 0.000 claims abstract description 14
230000001627 detrimental effect Effects 0.000 claims abstract description 12
230000001965 increasing effect Effects 0.000 claims abstract description 9
SYGWGHVTLUBCEM-ZIZPXRJBSA-N Urocortisone Chemical compound C1[C@H](O)CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CC[C@@H]21 SYGWGHVTLUBCEM-ZIZPXRJBSA-N 0.000 claims description 85
AODPIQQILQLWGS-GXBDJPPSSA-N tetrahydrocortisol Chemical compound C1[C@H](O)CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CC[C@@H]21 AODPIQQILQLWGS-GXBDJPPSSA-N 0.000 claims description 80
SYGWGHVTLUBCEM-UHFFFAOYSA-N (3alpha,5alpha,17alphaOH)-3,17,21-Trihydroxypregnane-11,20-dione Natural products C1C(O)CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC21 SYGWGHVTLUBCEM-UHFFFAOYSA-N 0.000 claims description 79
AODPIQQILQLWGS-UHFFFAOYSA-N (3alpa,5beta,11beta,17alphaOH)-form-3,11,17,21-Tetrahydroxypregnan-20-one, Natural products C1C(O)CCC2(C)C3C(O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC21 AODPIQQILQLWGS-UHFFFAOYSA-N 0.000 claims description 67
UPTAPIKFKZGAGM-FAIYVORSSA-N 3alpha,17alpha,21-Trihydroxy-5beta-pregnan-20-one Chemical compound C1[C@H](O)CC[C@]2(C)[C@H]3CC[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CC[C@@H]21 UPTAPIKFKZGAGM-FAIYVORSSA-N 0.000 claims description 41
238000000034 method Methods 0.000 claims description 34
UPTAPIKFKZGAGM-UHFFFAOYSA-N (3alpha,5alpha,17alphaOH)-3,17,21-Trihydroxypregnan-20-one Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)(O)C(=O)CO)C4C3CCC21 UPTAPIKFKZGAGM-UHFFFAOYSA-N 0.000 claims description 29
229920002385 Sodium hyaluronate Polymers 0.000 claims description 29
229940010747 sodium hyaluronate Drugs 0.000 claims description 29
YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 29
230000009885 systemic effect Effects 0.000 claims description 27
229960004805 melengestrol Drugs 0.000 claims description 24
229960004616 medroxyprogesterone Drugs 0.000 claims description 23
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 22
229920000669 heparin Polymers 0.000 claims description 22
229960002897 heparin Drugs 0.000 claims description 22
DBPWSSGDRRHUNT-CEGNMAFCSA-N 17α-hydroxyprogesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DBPWSSGDRRHUNT-CEGNMAFCSA-N 0.000 claims description 18
UDKABVSQKJNZBH-DWNQPYOZSA-N Melengestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC(=C)[C@](OC(=O)C)(C(C)=O)[C@@]1(C)CC2 UDKABVSQKJNZBH-DWNQPYOZSA-N 0.000 claims description 18
VXIMPSPISRVBPZ-NWUMPJBXSA-N megestrol Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 VXIMPSPISRVBPZ-NWUMPJBXSA-N 0.000 claims description 18
229960001786 megestrol Drugs 0.000 claims description 18
230000008569 process Effects 0.000 claims description 18
239000006071 cream Substances 0.000 claims description 17
230000000699 topical effect Effects 0.000 claims description 16
239000006210 lotion Substances 0.000 claims description 15
PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 claims description 15
231100000252 nontoxic Toxicity 0.000 claims description 15
230000003000 nontoxic effect Effects 0.000 claims description 15
239000000243 solution Substances 0.000 claims description 14
230000000638 stimulation Effects 0.000 claims description 13
239000000829 suppository Substances 0.000 claims description 13
DBPWSSGDRRHUNT-UHFFFAOYSA-N 17alpha-hydroxy progesterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C(=O)C)(O)C1(C)CC2 DBPWSSGDRRHUNT-UHFFFAOYSA-N 0.000 claims description 12
CQOQDQWUFQDJMK-SSTWWWIQSA-N 2-methoxy-17beta-estradiol Chemical compound C([C@@H]12)C[C@]3(C)[C@@H](O)CC[C@H]3[C@@H]1CCC1=C2C=C(OC)C(O)=C1 CQOQDQWUFQDJMK-SSTWWWIQSA-N 0.000 claims description 12
150000001242 acetic acid derivatives Chemical class 0.000 claims description 12
230000009471 action Effects 0.000 claims description 12
230000037396 body weight Effects 0.000 claims description 12
230000006698 induction Effects 0.000 claims description 12
239000000546 pharmaceutical excipient Substances 0.000 claims description 12
PEXPJFWTSZLEAQ-UHFFFAOYSA-N 2-Methoxyoestriol Natural products C12CCC3(C)C(O)C(O)CC3C2CCC2=C1C=C(OC)C(O)=C2 PEXPJFWTSZLEAQ-UHFFFAOYSA-N 0.000 claims description 11
AVCFXYYRWRZONV-UHFFFAOYSA-N 2-methoxy-oestradiol-3-methyl ether Natural products C1CC2C3CCC(O)C3(C)CCC2C2=C1C=C(OC)C(OC)=C2 AVCFXYYRWRZONV-UHFFFAOYSA-N 0.000 claims description 10
239000000499 gel Substances 0.000 claims description 10
239000007921 spray Substances 0.000 claims description 9
239000003795 chemical substances by application Substances 0.000 claims description 8
239000002674 ointment Substances 0.000 claims description 8
208000014617 hemorrhoid Diseases 0.000 claims description 7
230000007998 vessel formation Effects 0.000 claims description 7
QOVGIKUHSFCSIK-NWUMPJBXSA-N (8r,9s,10r,13s,14s,17r)-17-acetyl-17-hydroxy-6,10,13-trimethyl-2,4,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-3-one Chemical compound C1C(C)=C2CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 QOVGIKUHSFCSIK-NWUMPJBXSA-N 0.000 claims description 6
XQRNVMXXOLTAJU-NWUMPJBXSA-N (8r,9s,10r,13s,14s,17r)-17-acetyl-17-hydroxy-6,10,13-trimethyl-9,11,12,14,15,16-hexahydro-8h-cyclopenta[a]phenanthren-3-one Chemical compound C1=C(C)C2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 XQRNVMXXOLTAJU-NWUMPJBXSA-N 0.000 claims description 6
DILDHNKDVHLEQB-YVRXZLTFSA-N (8r,9s,13s,14s)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-2,3,17-triol Chemical compound OC1=C(O)C=C2[C@H]3CC[C@](C)(C(CC4)O)[C@@H]4[C@@H]3CCC2=C1 DILDHNKDVHLEQB-YVRXZLTFSA-N 0.000 claims description 6
SWINWPBPEKHUOD-JPVZDGGYSA-N 2-hydroxyestrone Chemical compound OC1=C(O)C=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 SWINWPBPEKHUOD-JPVZDGGYSA-N 0.000 claims description 6
208000025865 Ulcer Diseases 0.000 claims description 6
MULICLCRGFYQJF-LLTWYMBTSA-N [2-[(3r,5r,8s,9s,10s,13s,14s,17r)-3,17-dihydroxy-10,13-dimethyl-11-oxo-2,3,4,5,6,7,8,9,12,14,15,16-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@](C(=O)COC(=O)C)(O)[C@@]2(C)CC1=O MULICLCRGFYQJF-LLTWYMBTSA-N 0.000 claims description 6
OJUZFZGYANUVTJ-YRZKEEBRSA-N [2-oxo-2-[(3r,5r,8s,9s,10s,11s,13s,14s,17r)-3,11,17-trihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-17-yl]ethyl] acetate Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@](C(=O)COC(=O)C)(O)[C@@]2(C)C[C@@H]1O OJUZFZGYANUVTJ-YRZKEEBRSA-N 0.000 claims description 6
239000003085 diluting agent Substances 0.000 claims description 6
239000000262 estrogen Substances 0.000 claims description 6
230000035876 healing Effects 0.000 claims description 6
230000001939 inductive effect Effects 0.000 claims description 6
238000011200 topical administration Methods 0.000 claims description 6
231100000397 ulcer Toxicity 0.000 claims description 6
230000001133 acceleration Effects 0.000 claims description 5
210000004204 blood vessel Anatomy 0.000 claims description 5
238000004519 manufacturing process Methods 0.000 claims description 5
IBVAQQYNSHJXBV-UHFFFAOYSA-N adipic acid dihydrazide Chemical compound NNC(=O)CCCCC(=O)NN IBVAQQYNSHJXBV-UHFFFAOYSA-N 0.000 claims description 4
239000002552 dosage form Substances 0.000 claims description 4
230000012010 growth Effects 0.000 claims description 4
230000026341 positive regulation of angiogenesis Effects 0.000 claims description 4
230000004936 stimulating effect Effects 0.000 claims description 4
210000000988 bone and bone Anatomy 0.000 claims description 3
208000015181 infectious disease Diseases 0.000 claims description 3
241000282412 Homo Species 0.000 claims description 2
210000004877 mucosa Anatomy 0.000 claims description 2
238000002560 therapeutic procedure Methods 0.000 claims description 2
CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 claims 3
230000002542 deteriorative effect Effects 0.000 abstract 1
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 24
238000012360 testing method Methods 0.000 description 12
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
230000001684 chronic effect Effects 0.000 description 11
239000011780 sodium chloride Substances 0.000 description 11
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 9
238000009472 formulation Methods 0.000 description 9
MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 8
102000004169 proteins and genes Human genes 0.000 description 8
108090000623 proteins and genes Proteins 0.000 description 8
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 7
MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 7
241001529936 Murinae Species 0.000 description 7
241000699670 Mus sp. Species 0.000 description 7
238000003556 assay Methods 0.000 description 7
229960004544 cortisone Drugs 0.000 description 7
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
239000003246 corticosteroid Substances 0.000 description 6
229960001334 corticosteroids Drugs 0.000 description 6
230000002792 vascular Effects 0.000 description 6
239000002158 endotoxin Substances 0.000 description 5
229910001385 heavy metal Inorganic materials 0.000 description 5
238000011835 investigation Methods 0.000 description 5
244000005700 microbiome Species 0.000 description 5
239000000843 powder Substances 0.000 description 5
238000007920 subcutaneous administration Methods 0.000 description 5
206010061218 Inflammation Diseases 0.000 description 4
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
240000004808 Saccharomyces cerevisiae Species 0.000 description 4
229910052785 arsenic Inorganic materials 0.000 description 4
RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 4
230000008033 biological extinction Effects 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
239000003814 drug Substances 0.000 description 4
239000008187 granular material Substances 0.000 description 4
230000004054 inflammatory process Effects 0.000 description 4
125000000896 monocarboxylic acid group Chemical group 0.000 description 4
241000588724 Escherichia coli Species 0.000 description 3
102100023122 Glycylpeptide N-tetradecanoyltransferase 2 Human genes 0.000 description 3
101710081889 Glycylpeptide N-tetradecanoyltransferase 2 Proteins 0.000 description 3
230000002491 angiogenic effect Effects 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
229940079593 drug Drugs 0.000 description 3
238000001035 drying Methods 0.000 description 3
-1 ester derivatives of hyaluronic acid Chemical class 0.000 description 3
238000002329 infrared spectrum Methods 0.000 description 3
239000000463 material Substances 0.000 description 3
230000000813 microbial effect Effects 0.000 description 3
230000036961 partial effect Effects 0.000 description 3
235000019624 protein content Nutrition 0.000 description 3
239000008213 purified water Substances 0.000 description 3
238000011084 recovery Methods 0.000 description 3
239000013557 residual solvent Substances 0.000 description 3
238000001228 spectrum Methods 0.000 description 3
239000008223 sterile water Substances 0.000 description 3
MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
241000722985 Fidia Species 0.000 description 2
IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 2
OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 2
MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 2
208000004210 Pressure Ulcer Diseases 0.000 description 2
206010040943 Skin Ulcer Diseases 0.000 description 2
IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
235000012730 carminic acid Nutrition 0.000 description 2
238000011260 co-administration Methods 0.000 description 2
230000015271 coagulation Effects 0.000 description 2
238000005345 coagulation Methods 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000012634 fragment Substances 0.000 description 2
229960002442 glucosamine Drugs 0.000 description 2
229940097043 glucuronic acid Drugs 0.000 description 2
230000005484 gravity Effects 0.000 description 2
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
230000036512 infertility Effects 0.000 description 2
230000002757 inflammatory effect Effects 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
229910052742 iron Inorganic materials 0.000 description 2
229950006780 n-acetylglucosamine Drugs 0.000 description 2
239000013618 particulate matter Substances 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
231100000019 skin ulcer Toxicity 0.000 description 2
159000000000 sodium salts Chemical class 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
201000004624 Dermatitis Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
229920002683 Glycosaminoglycan Polymers 0.000 description 1
108010003272 Hyaluronate lyase Proteins 0.000 description 1
102000001974 Hyaluronidases Human genes 0.000 description 1
208000005230 Leg Ulcer Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
206010061137 Ocular toxicity Diseases 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
108090000526 Papain Proteins 0.000 description 1
239000004365 Protease Substances 0.000 description 1
241000589517 Pseudomonas aeruginosa Species 0.000 description 1
241000191967 Staphylococcus aureus Species 0.000 description 1
108010085012 Steroid Receptors Proteins 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
206010044245 Toxic optic neuropathy Diseases 0.000 description 1
MUCRYNWJQNHDJH-OADIDDRXSA-N Ursonic acid Chemical compound C1CC(=O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C MUCRYNWJQNHDJH-OADIDDRXSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000000061 acid fraction Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
230000001772 anti-angiogenic effect Effects 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000005388 borosilicate glass Substances 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
229920001577 copolymer Chemical class 0.000 description 1
229940117173 croton oil Drugs 0.000 description 1
229960003957 dexamethasone Drugs 0.000 description 1
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
239000005308 flint glass Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000003163 gonadal steroid hormone Substances 0.000 description 1
208000010758 granulomatous inflammation Diseases 0.000 description 1
239000003966 growth inhibitor Substances 0.000 description 1
229960002773 hyaluronidase Drugs 0.000 description 1
229960000890 hydrocortisone Drugs 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
229960002985 medroxyprogesterone acetate Drugs 0.000 description 1
230000002906 microbiologic effect Effects 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
231100000956 nontoxicity Toxicity 0.000 description 1
231100000327 ocular toxicity Toxicity 0.000 description 1
229940055729 papain Drugs 0.000 description 1
235000019834 papain Nutrition 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
238000009781 safety test method Methods 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
206010040882 skin lesion Diseases 0.000 description 1
231100000444 skin lesion Toxicity 0.000 description 1
229940049529 sodium hyaluronate 20 mg/ml Drugs 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
102000005969 steroid hormone receptors Human genes 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000017423 tissue regeneration Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
231100000041 toxicology testing Toxicity 0.000 description 1
210000005166 vasculature Anatomy 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

CA002208916A 1997-07-03 1997-07-03 Promotion de la cicatrisation a l'aide de steroides ayant des effets secondaires systemiques reduits comparativement a ceux habituellement associes aux glucocorticoides, aux mineralcorticoides et aux steroides sexuels Abandoned CA2208916A1 (fr)

Priority Applications (3)

Application Number	Priority Date	Filing Date	Title
CA002208916A CA2208916A1 (fr)	1997-07-03	1997-07-03	Promotion de la cicatrisation a l'aide de steroides ayant des effets secondaires systemiques reduits comparativement a ceux habituellement associes aux glucocorticoides, aux mineralcorticoides et aux steroides sexuels
AU82021/98A AU8202198A (en)	1997-07-03	1998-07-03	Pharmaceutical compositions comprising an angiostatic steroid combined with a hyaluronan
PCT/CA1998/000649 WO1999001142A1 (fr)	1997-07-03	1998-07-03	Compositions pharmaceutiques comprenant un steroide angiostatique combine a un hyaluronan

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA002208916A CA2208916A1 (fr)	1997-07-03	1997-07-03	Promotion de la cicatrisation a l'aide de steroides ayant des effets secondaires systemiques reduits comparativement a ceux habituellement associes aux glucocorticoides, aux mineralcorticoides et aux steroides sexuels

Publications (1)

Publication Number	Publication Date
CA2208916A1 true CA2208916A1 (fr)	1999-01-03

Family

ID=4160953

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002208916A Abandoned CA2208916A1 (fr)	1997-07-03	1997-07-03	Promotion de la cicatrisation a l'aide de steroides ayant des effets secondaires systemiques reduits comparativement a ceux habituellement associes aux glucocorticoides, aux mineralcorticoides et aux steroides sexuels

Country Status (3)

Country	Link
AU (1)	AU8202198A (fr)
CA (1)	CA2208916A1 (fr)
WO (1)	WO1999001142A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5504074A (en)	1993-08-06	1996-04-02	Children's Medical Center Corporation	Estrogenic compounds as anti-angiogenic agents
US6908910B2 (en)	1993-08-06	2005-06-21	The Children's Medical Center Corporation	Estrogenic compounds as anti-mitotic agents
US7087592B1 (en)	1999-08-23	2006-08-08	Entre Med, Inc.	Compositions comprising purified 2-methoxyestradiol and methods of producing same
US7135581B2 (en)	2000-08-18	2006-11-14	Entremed, Inc.	Antiangiogenic agents
US6995278B2 (en)	2000-08-18	2006-02-07	Entre Med, Inc.	Antiangiogenic agents
AU8838601A (en) *	2000-11-27	2002-06-03	Entremed Inc	Antiangiogenic agents
JP2006526025A (ja)	2003-05-28	2006-11-16	エントレメッドインコーポレイテッド	抗血管新生剤
EP1756139A4 (fr)	2004-03-12	2009-07-29	Entremed Inc	Agents anti-angiogeniques
CA2646065C (fr)	2006-03-20	2014-01-14	Entremed, Inc.	2-methoxyestradiol presentant une activite anti-arthritique pouvant modifier l'evolution de la maladie
FR2918892B1 (fr) *	2007-07-16	2010-02-12	Fabre Pierre Dermo Cosmetique	Composition dermatologique anti-inflammatoire comprenant des corticoides et des fragments de hyaluronate, et ses utilisations

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4946870A (en) *	1986-06-06	1990-08-07	Union Carbide Chemicals And Plastics Company Inc.	Delivery systems for pharmaceutical or therapeutic actives
WO1990015816A1 (fr) *	1989-06-16	1990-12-27	The Upjohn Company	Composes du type suramine et steroides angiostatiques inhibiteurs de l'angiogenese

1997
- 1997-07-03 CA CA002208916A patent/CA2208916A1/fr not_active Abandoned
1998
- 1998-07-03 WO PCT/CA1998/000649 patent/WO1999001142A1/fr not_active Ceased
- 1998-07-03 AU AU82021/98A patent/AU8202198A/en not_active Abandoned

Also Published As

Publication number	Publication date
AU8202198A (en)	1999-01-25
WO1999001142A1 (fr)	1999-01-14

Legal Events

Date	Code	Title	Description
1997-07-03	EEER	Examination request
2000-07-04	FZDE	Dead

Publication	Publication Date	Title
US5529987A (en)	1996-06-25	Hyaluronic acid-urea pharmaceutical compositions and uses
US5166331A (en)	1992-11-24	Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same
FI79554B (fi)	1989-09-29	Foerfarande foer framstaellning av hyaluronsyrafraktioner med farmaceutisk aktivitet.
US6537978B1 (en)	2003-03-25	Oral administration of effective amounts of forms of hyaluronic acid
EP0716596B1 (fr)	2007-06-20	Nouvelles compositions pharmaceutiques a usage topique renfermant de l'acide hyaluronique et ses derives
JPH09512797A (ja)	1997-12-22	癌の治療および転移の予防
JPH11504899A (ja)	1999-05-11	獣医学および医学用途用化合物
CA2417867C (fr)	2012-09-11	Procedes servant a prevenir ou a traiter des maladies et des etats au moyen de glucides complexes
US5550112A (en)	1996-08-27	Hyaluronic acid-urea pharmaceutical compositions and uses
AU694113B2 (en)	1998-07-16	Compositions, for inhibition, control and regression of angiogenesis, containing hyaluronic acid and NSAID
WO1999001142A1 (fr)	1999-01-14	Compositions pharmaceutiques comprenant un steroide angiostatique combine a un hyaluronan
EP0988040B1 (fr)	2004-07-28	Utilisation de glucosamine et de derives de glucosamine pour le soulagement rapide de prurit ou de douleurs localisees
EP0434625B1 (fr)	1995-04-19	IGF-I pour le traitement des effets secondaires dans le traitement par stéroides
US6596703B1 (en)	2003-07-22	Promotion of wound healing utilizing steroids having reduced deteriorous systemic side effects typical of glucocorticoids, mineralocorticoids and sex steroids
KR20080031394A (ko)	2008-04-08	Ｔｇｆ-베타 수퍼패밀리 구성원을 포함하는 약학 조성물
US20050187185A1 (en)	2005-08-25	Pharmaceutical applications of hyaluronic acid preparations
AP619A (en)	1997-10-10	Use of hyaluronic acid or salt for the treatment of a human having a stroke or myocardial infarction.
WO1999002151A1 (fr)	1999-01-21	Compositions de paclitaxel contenant un acide hyaloronique de poids moleculaire inferieur a 750 000 da
CA1338554C (fr)	1996-08-27	Combination de tobramycine et de steroides pour applications ophtalmologiques topiques
EP1393749A1 (fr)	2004-03-03	Préparation pharmaceutique en forme colloidale pour le traitement des maladies de la peau, comprenant de l' acide hyluronique
RU2528905C1 (ru)	2014-09-20	Способ лечения ран мягких тканей различной этиологии
RU2223097C1 (ru)	2004-02-10	Комбинированное средство для лечения кожных заболеваний
JPH04208219A (ja)	1992-07-29	褥瘡及び皮膚潰瘍治療外用剤
KR19990018307A (ko)	1999-03-15	상처치료용 의약조성물
Bhatia et al.	2004	Cicatrização de vários tipos de úlceras com fenitoína